No Detail Found!

Clinical study of 400mg efavirenz treatment in newly diagnosed patients with HIV/AIDS

Author(s)
Tongtong Yang Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Ruifeng Zhou Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Yuanhong He Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Huanxia Liu Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Zhihui Guo Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Xia Zhao Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Taisheng Li Department of Infection, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,Beijing,China
Shenghua He Department of Infection, Chengdu Public Health Clinical Medical Center,Chengdu, Sichuan,China
Abstract
The efficacy of 400mg efavirenz (EFV) once daily is reported to be similar to that of 600mg EFV. However, EFV-related toxic and side effects of 400mg EFV are significantly reduced. Here, the feasibility of reducing EFV to 400mg once a day in HIV-infected/AIDS patients was evaluated. Fifty patients were included. Patients were given 3TC+TDF+400mg EFV (n=25) or 3TC+TDF+600mg EFV (n=25). The proportion of patients with HIV RNA 0.05). No serious adverse events of the central nervous system occurred. The incidence of depression, sleep disturbance, and vertigo were similar (P>0.05). The efficacy of 400mg EFV is comparable to 600mg EFV. However, patients receiving 400mg EFV have fewer adverse events.
Publication Details
Page(s) 367-375
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 37, Issue: 2, Year: 2024

Request the full text from PASTIC

Keywords
AIDS, Antiviral therapy, efavirenz, HIV
0

Citations

0

Downloads

112

Views